Data Readout

Design Therapeutics builds on DT-216P2 frataxin gains ahead of H2 2026 update

The RESTORE-FA trial already showed dose-dependent frataxin increases and a 6.4-point mFARS improvement at four weeks; the pending update will test whether that holds through 12 weeks of dosing.

By AppliedXLJuly 13, 2026Trial NCT06874010

Executive Summary

Design Therapeutics is heading toward a maturation readout, not a first look: the trial has already shown frataxin increases and a functional signal at an earlier timepoint, and the pending update tests whether that holds at a longer dosing duration.
The sponsor has tied its next strategic step, a potential registrational path, to this body of evidence, raising what the update needs to show to support that plan.
The asset sits in a small field of frataxin-targeted competitors in Friedreich ataxia, none of which have yet reached a resolved late-stage outcome on this mechanism.
The trial's enrollment and protocol have stayed stable since dosing began, so the update's credibility rests on the clinical result itself rather than on operational execution.

The catalyst

Design Therapeutics said it anticipates reporting data, including frataxin (FXN) expression based on 12 weeks of dosing, from the RESTORE-FA Phase 1/2 multiple ascending dose trial of DT-216P2 in the second half of 2026. The trial, NCT06874010, is a Phase 1/2 study in Friedreich ataxia running outside the United States, with an anticipated enrollment of 20 patients and a primary completion date of December 1, 2026. The registered primary endpoint is the frequency of treatment-emergent adverse events, with frataxin expression tracked as a secondary measure. Design+1

Probability of Success

Endpoint Met40%

Completes81%

Clinical Significance55%

Regulatory35%

What already happened

This is not the trial's first data disclosure. Design reported four-week intravenous data from the same trial on May 18, 2026, showing dose-dependent increases in frataxin mRNA and protein: whole blood frataxin rose 65%, muscle frataxin rose 42%, and protein-level increases of 22% to 27% carried reported p-values. Patients on the 1 mg/kg dose showed a mean improvement of 6.4 points on the modified Friedreich Ataxia Rating Scale (mFARS), a validated measure of disease severity, after four weeks. The company reported no serious adverse events or discontinuations at that readout and described the safety profile as favorable. Design said it intends to pursue a registrational path based on these data and will provide an update on its plans in the fourth quarter of 2026. Design

What the update will test

The pending second-half-2026 disclosure extends the dosing window from four weeks to twelve, testing whether the frataxin increase and the functional improvement seen early persist or deepen with longer exposure. Frataxin deficiency is the root cause of Friedreich ataxia, and demonstrating a durable, dose-dependent increase in the protein is the biological rationale for any downstream clinical benefit. The trial's small size, an anticipated 20 patients, means the 12-week update will be informative on direction and durability but will carry limited statistical weight on its own. Design+1

Competitive standing

DT-216P2 shares its frataxin target with two other clinical-stage programs: Larimar Therapeutics' nomlabofusp, in a Phase 2 trial (NCT06447025), and Solid Biosciences' SGT-212, a Phase 1 gene therapy (NCT07180355). Design's own earlier formulation, DT-216, was tested in a separate Phase 1 trial (NCT05285540) before the company moved to the current DT-216P2 formulation. None of these frataxin-directed programs has reached a resolved late-stage readout in the indication; the broader Friedreich ataxia field includes several later-stage programs, such as Biogen's omaveloxolone in Phase 3 and PTC Therapeutics' vatiquinone in Phase 3, but those act through different mechanisms and are not direct comparators to a frataxin-restoring approach. The trial's enrollment has held flat at its original target of 20 patients since the study began, a routine signal for a Phase 1/2 program of this size. NCT06874010

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.